Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration was received with the support of ICM d.o.o partner and is valid for 5 years. The first deliveries shall start in June 2020.
More
Biotechnological company BIOCAD has announced the research in order to create an
Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina.
MoreBiotechnological company BIOCAD has announced the research in order to create an mRNA vaccine against SARS-COV-2 (coronavirus). Development will be
More
